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Background: Use of short-acting β2-agonists in chronic obstructive pulmonary disease (COPD) 
during treatment with long-acting β2-agonists is recommended as needed, but its effectiveness 
is unclear. The purpose of this study was to assess the additional bronchodilating effect of 
increasing doses of salbutamol during acute and chronic treatment with formoterol in patients 
with COPD.
Methods: Ten patients with COPD underwent a dose-response curve to salbutamol (until 
800 µg of cumulative dose) after a 1-week washout (baseline), 8 hours after the first administra-
tion of formoterol 12 µg (day 1), and after a 12-week and 24-week period of treatment with 
formoterol (12 µg twice daily by dry powder inhaler). Peak expiratory flow, forced expiratory 
volume in one second (FEV1), forced vital capacity, and inspiratory capacity were measured at 
the different periods of treatment and at different steps of the dose-response curve.
Results: Despite acute or chronic administration of formoterol, maximal values of peak expira-
tory flow, FEV1, and forced vital capacity after 800 µg of salbutamol were unchanged compared 
with baseline. The baseline FEV1 dose-response curve was steeper than that at day 1, week 12, 
or week 24 (P , 0.0001). Within each dose-response curve, FEV1 was different only at baseline 
and at day 1 (P , 0.001), when FEV1 was still greater at 800 µg than at 0 µg (P , 0.02). 
In contrast, the forced vital capacity dose-response curves were similar at the different periods, 
while within each dose-response curve, forced vital capacity was different in all instances 
(P , 0.001), always being higher at 800 µg than at 0 µg (P , 0.05).
Conclusion: In patients with stable COPD, the maximal effect of salbutamol on peak expira-
tory flow, FEV1, and forced vital capacity was unchanged after either acute or chronic treatment 
with formoterol. With increasing doses of salbutamol, FEV1 increased only after acute admin-
istration of formoterol. Forced vital capacity also significantly improved during long-term 
treatment with formoterol.
Keywords: chronic obstructive pulmonary disease, salbutamol, formoterol, long-acting 
β2-agonists
Introduction
The effect of increasing doses of short-acting β2-agonists (SABA) in patients with stable 
COPD during long-term treatment with long-acting β2-agonists (LABA) is presently 
unknown. The current guidelines recommend treating COPD patients with bronchodilat-
ing drugs,1 and among them, LABA are widely used.2–4 Indeed, although changes in 
forced expiratory volume in one second (FEV1) after acute or chronic administration of 
bronchodilating agents are usually scarce in COPD, other volume parameters, such as 
inspiratory capacity and forced vital capacity, must be taken into account to assess the 
effectiveness of therapy with bronchodilators in these patients.5 During regular LABA International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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treatment, if the airflow obstruction increases abruptly, a 
therapeutic option is to add SABA as rescue medication, trying 
to achieve rapid and effective control of airway obstruction 
and related symptoms.   However, regular treatment with LABA 
could reduce the bronchodilatory response to repeated doses 
of SABA because of occupation or potential downregulation 
of β2   adrenoreceptors.6 Cazzola et al performed a placebo- 
controlled study of the effect of acute pretreatment with LABA 
(salmeterol, formoterol, or oxitropium via metered dose 
inhaler) on the bronchodilating response to incremental doses 
of inhaled salbutamol in a cohort of patients with COPD and 
marked reversibility of airway obstruction, as assessed by 
acute FEV1 change.7 All long-acting bronchodilators elicited 
a significant increase in FEV1, and a significant dose-dependent 
increment in FEV1 was seen after salbutamol administration, 
suggesting that salbutamol is useful as a “rescue agent” in 
COPD when using long-acting bronchodilators, including 
LABA.7 However, this study did not address the relevant 
clinical question of whether or not similar results would be 
obtained after long-term use of LABA in patients with COPD.8 
Therefore, the aim of the present study was to assess if the 
main indices of airway obstruction are positively affected in 
the dose-response curve to inhaled salbutamol not only after 
acute but also after chronic treatment with formoterol, a long-
acting pure β2-agonist, in patients with stable COPD.
Methods
Approval of our ethics committee was obtained prior to 
embarking on this research. After providing their written 
informed consent, 15 consecutive patients were enrolled, 
suffering from COPD with moderate-to-severe airway 
obstruction, defined according to the following criteria: smok-
ing history of more than 20 pack-years and/or presence of 
other known risk factors for COPD (frequent respiratory tract 
infections in childhood, chronic cough and phlegm, occupa-
tional exposures, indoor pollutants by biomass fuel, 
α1-antitrypsin deficiency); baseline FEV1/vital capacity 
ratio , 5th percentile of lower limit of normal, corresponding 
to a FEV1/vital capacity ratio , 88% predicted9,10 and a base-
line FEV1 , 80% predicted and .30% predicted; increase 
of FEV1 , 10% of predicted and 200 mL after 400 µg of 
inhaled salbutamol;9,10 absence of history of bronchial asthma, 
allergic rhinitis or atopy; and no concomitant restrictive lung 
or chest wall disorders. To be eligible for the study, patients 
had to be in a stable condition without any symptoms or treat-
ment changes in the 4 weeks prior to the study, have had no 
exacerbations in the preceding 12 weeks, and be able to per-
form forced expiratory maneuvers adequately. No patient was 
  suffering from known cardiovascular disease, a   neuromuscular 
disorder, or any metabolic or hormonal alterations. All patients 
treated with inhaled corticosteroids had to stop these drugs 
at least 4 weeks before the beginning of the study. No other 
concomitant drugs were allowed during the study, except for 
SABA as rescue medication. On the first day, patients were 
asked to withdraw any LABA for one week and SABA for 
12 hours before starting the study.
After the washout period, each patient performed spirom-
etry with a maximal flow/volume curve, underwent measure-
ment of DLCO (diffusing capacity of the lung for carbon 
monoxide) and lung volumes by the multibreath helium 
dilution method, and assessment of tidal expiratory flow 
limitation with the negative expiratory pressure technique.11 
Afterwards, they underwent a dose-response curve to salbu-
tamol, performing a series of spirometric maneuvers with 
maximal expiratory flow/volume curve 20 minutes after 
inhalation (metered dose inhaler + spacer) of subsequent 
doses of salbutamol (0 µg, 100 µg, 100 µg, 200 µg, 400 µg), 
reaching a cumulative dose of 800 µg at baseline period. 
Treatment with formoterol dry powder inhaler 12 µg twice 
daily was then prescribed, starting from the following morn-
ing with no other inhaled drug. In all patients, the dose- 
response curve to salbutamol as previously described was 
repeated on the first day of treatment, and after 12 weeks and 
24 weeks. These tests were always performed eight hours 
after the morning dose of formoterol. The maximal cumula-
tive dose of salbutamol of 800 µg was chosen to avoid the 
potentially dangerous effects of acute β2 stimulation on 
cardiac function elicited by higher doses of the drug and 
because it is highly improbable that patients with COPD 
would use more than eight puffs of salbutamol as a single 
rescue dose in real life. On each occasion, inspiratory capac-
ity was measured prior to the maximal expiratory flow-
volume curve by inspiring from end expiratory lung volume 
to total lung capacity. The predicted inspiratory capacity 
values were those proposed by Tantucci et al.12
Adherence to treatment with formoterol was assessed at 
each period by checking the dose counter of the dry powder 
inhaler. Monitoring of side effects was performed by evaluat-
ing heart rate and blood pressure values before and after each 
dose of salbutamol.
spirometry
A computerized water-sealed light-bell Stead-Wells spirom-
eter (Biomedin, Padua, Italy) was used and the operator was 
assisted during the test with software able to verify both accept-
ability and repeatability of spirometric maneuvers online. International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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All measurements were made in accordance with the   guidelines 
of the American Thoracic Society,9,10 with the subjects in the 
sitting position, wearing a nose clip. During the study, the neck 
was held in a fixed neutral position to avoid changes associated 
with different neck positions, and no inspiratory pause was 
allowed at total lung capacity before performing the forced 
expiratory maneuver. We adopted the reference values for 
pulmonary function parameters proposed by Quanjer et al.13
negative expiratory pressure test
The patients breathed quietly, wearing a nose clip, through a 
mouthpiece and a heated pneumotachograph (Series 3700; 
Hans Rudolph, Kansas City, MO) connected to a differential 
pressure transducer (Raytech DP55 ± 3 cm H2O; Raytech 
Instruments, Vancouver, Canada) to measure flow. Pressure 
was measured at the mouth by a differential pressure trans-
ducer (Raytech DP55 ± 100 cm H2O). The pneumotachograph 
was assembled in series with a Venturi device that created a 
negative pressure in the circuit which could be precisely fixed. 
This technique is described fully elsewhere.5,11
statistical analysis
The sample size of 15 provided a statistical power of 90% 
(β = 0.10) to detect the smallest clinically relevant mean dif-
ference of 140 mL of FEV1
14 with a standard deviation of the 
differences in response to bronchodilators of 140 mL of FEV1 
found in our laboratory at 5% of significance level (β = 0.05) 
for a paired t-test. Average data of the variables of interest 
were compared by multifactorial analysis of variance to 
establish any significant overall effect among the four periods. 
If significant, Sheffé multiple range test was used to identify 
which differences were significant. Analysis of variance for 
repeated measures with the Bonferroni correction was per-
formed to analyze and compare data within the dose-response 
curve of each period (baseline, day 1, week 12, week 24). 
A P value , 0.05 was considered to be statistically significant. 
Data are expressed as means ± standard deviation. Statistical 
analysis was performed using the Stat View software package 
(Stat View; SAS Institute Inc, Cary, NC).
Results
Five of the 15 patients dropped out (four because of noncom-
pliance with LABA and one because of an exacerbation at 
week 10), and 10 (including seven males) successfully com-
pleted the study. Anthropometric and functional data are 
shown in Table 1. Three patients were flow-limited at rest 
during tidal expiration in the sitting position with an inspira-
tory capacity of 56.6% ± 12.0% predicted, while seven 
patients were not flow-limited and had a normal inspiratory 
capacity of 94.0% ± 7.8% predicted. All patients were former 
smokers (range 20–54 pack-years). All patients had quit 
smoking at least 1 year before enrolling in this study and no 
patient smoked before the pulmonary function test. No changes 
in smoking habit were observed and no exacerbation was 
reported among patients who completed the protocol.
Mean values for FEV1, forced vital capacity, peak 
  expiratory flow, FEV1/forced vital capacity, and inspiratory 
capacity, and the response to subsequent cumulative doses 
of salbutamol at baseline, day 1, week 12, and week 24 
periods are shown in Table 2. The FEV1 and forced vital 
capacity dose-response curves to salbutamol at the different 
periods are shown in Figure 1.
Table 1 Anthropometric and functional data of patients who were enrolled (n = 15) and who completed the study (n = 10)
(n = 15) (n = 10)
gender (M/F) 11M/4F 7M/3F
Age (yrs) 63.4 ± 10.6 61.7 ± 10.4
Body weight (kg) 69.5 ± 13.0 70.5 ± 12.2
height (m) 1.63 ± 0.1 1.62 ± 0.1
BMI (kg/m2) 26.1 ± 4.0 26.7 ± 4.0
Absolute values (% predicted) Absolute values (% predicted)
FeV1/VC 43.7% ± 11.1%   57.5 ± 15.2 40.9% ± 11.0%   53.5 ± 14.7
FeV1 1.36 ± 0.51 L   53.3 ± 16.5 1.29 ± 0.53 L   50.4 ± 16.9
FVC 2.66 ± 0.69 L   83.4 ± 16.1 2.62 ± 0.81 L   82.5 ± 19.6
IC 2.29 ± 0.70 L   81.8 ± 12.6 2.24 ± 0.78 L   82.8 ± 20.2
TLC 5.49 ± 0.93 L   98.8 ± 17.9 5.76 ± 0.95 L 104.4 ± 15.8
FrC 3.24 ± 0.71 L 103.5 ± 23.2 3.42 ± 0.75 L 109.4 ± 25.8
rV 2.46 ± 0.62 L 115.7 ± 34.6 2.59 ± 0.66 L 123.7 ± 33.5
DLCO 12.24 ± 4.93 mL/min*mmhg   53.2 ± 20.9 12.8 ± 5.32 mL/min*mmhg   54.9 ± 22.9
Note: Data are mean ± standard deviation. 
Abbreviations: BMI, body mass index; DLCO, diffusing capacity of the lung for carbon monoxide; FrC, functional residual capacity; FeV1, forced expiratory volume in one 
second; FVC, forced vital capacity; IC, inspiratory capacity; TLC, total lung capacity; VC, vital capacity; rV, residual volume.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
402
La Piana et al
Following both acute and chronic administration of 
  formoterol, FEV1 before salbutamol (0 µg) was always higher 
when compared with baseline (day 1, week 12 and week 24 
versus baseline, P , 0.01, Figure 1 and Table 2).
At the different assessment periods, the dose-response 
curves were different for FEV1 (P , 0.01), and almost sig-
nificantly different for peak expiratory flow (P = 0.056), but 
this was not the case for forced vital capacity. In particular, 
the FEV1 dose-response curve at baseline was significantly 
steeper than those at day 1, week 12, and week 24 
(P , 0.0001, Figure 1).
Within each dose-response curve for salbutamol, FEV1 
values were significantly different only at baseline and 
day 1 (P , 0.001) and peak expiratory flow values only 
at baseline (P , 0.001), while forced vital capacity values 
remained significantly different at all periods of the study 
(P , 0.001). In particular, FEV1 increased significantly 
between dose 0 µg and dose 800 µg of salbutamol both at 
baseline and at day 1 (P , 0.05), and peak expiratory flow 
only at baseline (P , 0.01). In contrast, forced vital 
  capacity increased from dose 0 µg to dose 800 µg of 
salbutamol in all instances (P , 0.05, Table 2).
At each period of the study, the inspiratory capacity 
values showed no significant changes during incremental 
doses of salbutamol when all patients were included. This 
occurred because inspiratory capacity was normal and 
remained unchanged after bronchodilators in seven patients 
who were not flow-limited. However, if only three tidally 
flow-limited COPD patients were taken into account, a trend 
similar to that found for forced vital capacity was observed 
also for inspiratory capacity (Table 2).
Discussion
The main results of the study were: the maximal effect after 
the last dose of salbutamol on peak expiratory flow, FEV1, 
and forced vital capacity did not change compared with 
baseline at each period of treatment with formoterol; while 
the significant FEV1 increment occurring after salbutamol 
on top of the first dose of formoterol was lost during chronic 
treatment, a significant improvement in forced vital capacity 
was still observed during long-term treatment with formot-
erol, although always at the highest dose of salbutamol 
(800 µg); and no changes in inspiratory capacity were found 
in any patient, but at least in those with baseline tidal 
Table 2 Lung function parameters at baseline and at each period of treatment with formoterol for each cumulative dose of salbutamol
Period 0 μg 100 μg 200 μg 400 μg 800 μg
Baseline FeV1 50.4 ± 16.9 52.2 ± 16.2 54.4 ± 17.1 55.8 ± 16.2 58.2 ± 16.8*
FVC 82.5 ± 19.6 85.3 ± 18.8 88.2 ± 17.1 90.3 ± 16.93 92.3 ± 14.6*
PeF 55.6 ± 13.3 56.9 ± 11.2 58.8 ± 11.7 59.7 ± 13.1 60.0 ± 13.4*
FeV1/FVC (%) 48.6 ± 9.2 48.8 ± 8.3 50.4 ± 9.2 50.4 ± 7.9 50.9 ± 9.4
IC 82.8 ± 20.2 85.3 ± 18.8 88.2 ± 17.1 90.3 ± 16.9 91.3 ± 14.6
IC (3 FL pts) 56.6 ± 12.8 57.8 ± 13.4 61.6 ± 9.3 63.6 ± 13.7 67.4 ± 13.1
Day 1§ FeV1 55.2 ± 16.8 56.5 ± 15.9 58.1 ± 15.4 58.3 ± 15.4 58.7 ± 14.6*
FVC 86.2 ± 20.7 88.8 ± 19.2 91.5 ± 19.6 92.1 ± 18.4 92.7 ± 18.6*
PeF 59.1 ± 14.9 60.5 ± 14.6 61.4 ± 13.8 60.8 ± 14.3 62.2 ± 12.4
FeV1/FVC (%) 51.2 ± 7.7 50.9 ± 7.5 50.7 ± 7.8 52 ± 9.9 51.9 ± 9.0
IC 86.2 ± 20.7 88.8 ± 19.2 91.5 ± 19.7 92.1 ± 18.4 91.7 ± 18.7
IC (3 FL pts) 58.9 ± 10.3 64.4 ± 8.2 65.8 ± 6.7 66.5 ± 8.6 67.5 ± 7.2
Week 12§ FeV1 54.1 ± 17.6 54.5 ± 17.0 56.4 ± 15.7 56.4 ± 15.7 57.5 ± 16.4
FVC 85.2 ± 18.3 86.4 ± 18 87.2 ± 15.8 87.7 ± 15.7 90.0 ± 14.8*
PeF 58.1 ± 15.3 60 ± 12.8 57.3 ± 13.7 57.7 ± 13.7 59.9 ± 15.3
FeV1/FVC (%) 50.2 ± 8.1 50.4 ± 8.9 51.7 ± 8.0 51.1 ± 7.9 50.5 ± 8.5
IC 86.0 ± 18.9 86.9 ± 18.6 89.0 ± 18.2 89.8 ± 16.9 91.0 ± 19.3
IC (3 FL pts) 58.3 ± 13.0 60.7 ± 14.9 63.7 ± 14.9 64.6 ± 10.9 65.2 ± 9.9
Week 24§ FeV1 55.3 ± 18.6 56.3 ± 18.8 57.3 ± 18.2 57.3 ± 18.2 58.1 ± 18.7
FVC 88.1 ± 19.9 88.5 ± 20.9 90.3 ± 20.3 90.7 ± 20.8 92.5 ± 20.3*
PeF 57.5 ± 16.1 58.2 ± 17.3 58.1 ± 15.6 60.4 ± 17.4 60.6 ± 16.6
FeV1/FVC (%) 50.6 ± 8.3 50.6 ± 8.2 51.3 ± 8.1 50.7 ± 7.9 50.3 ± 8.3
IC 88.1 ± 19.5 88.5 ± 20.7 90.3 ± 20.7 90.7 ± 20.8 92.5 ± 20.4
IC (3 FL pts) 56.4 ± 9.2 57.8 ± 11.7 60.8 ± 12.4 64.9 ± 12.9 64.7 ± 12.9
Notes: Data are mean ± standard deviation and expressed as % predicted, except for FeV1/FVC ratio. *P , 0.05 versus 0 µg;  §P , 0.001 versus baseline for FeV1. 
Abbreviations: BMI, body mass index; DLCO, diffusing capacity of the lung for carbon monoxide; FrC, functional residual capacity; FeV1, forced expiratory volume in one 
second; FVC, forced vital capacity; IC, inspiratory capacity; TLC, total lung capacity; VC, vital capacity; ICFL, flow limited at rest.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Figure 1 FeV1 and FVC are shown as % predicted at baseline and at each period of treatment for each cumulative dose of salbutamol. 
Notes: *P , 0.05 versus 0 µg for FeV1 at 800 µg at baseline and day 1, and for FVC at 800 µg at all periods; §P , 0.001 versus baseline; symbols are means, bars are standard 
error of the mean.
Abbreviations: FeV1, forced expiratory volume in one second; FVC, forced vital capacity.
  expiratory flow limitation and resting dynamic hyperinflation, 
changes similar to forced vital capacity were observed also 
for inspiratory capacity.
Our goal was to assess the bronchodilating effect elicited 
by acute SABA administration in patients with stable 
  moderate-to-severe COPD during short-term and long-term 
treatment with LABA. Formoterol is a full LABA with a 
very rapid onset of bronchodilating action that lasts for about 
12 hours due to its lipophilic properties.15 In COPD, pro-
longed administration of formoterol at a dosage of 12 µg 
twice daily is associated with better FEV1 and peak expira-
tory flow values over time and significant improvement of 
clinical outcomes.16 However, the aim of this study was to 
measure functional changes and not clinical improvement.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Inhaled SABA that induce bronchodilation in a few 
minutes and reach maximal effect after 20–30 minutes are 
usually the preferred rescue bronchodilators for the treatment 
of either intermittent or worsening symptoms in patients with 
COPD. Clinical studies that have evaluated the effect of 
SABA during long-term treatment with LABA in patients 
with COPD are lacking.
Previously, the effect of doubling doses of salbutamol 
(until a cumulative dose of 800 µg) given two hours after 
acute administration of different long-acting bronchodilators, 
such as formoterol, salmeterol, and oxitropium, was inves-
tigated in patients with COPD characterized by marked acute 
reversibility of airflow obstruction.7 In these circumstances, 
the maximal bronchodilating effect obtained at the highest 
dose of salbutamol was unchanged after a single dose of both 
LABA and oxitropium, as compared with baseline. However, 
both FEV1 and forced vital capacity showed a significant 
increase with administration of salbutamol following acute 
pretreatment with either LABA or oxitropium.
In the present study, these results were confirmed at least 
for formoterol also after eight hours, although to a lesser 
extent due to the half dose of the drug (12 µg versus 24 µg) 
and mainly due to the different phenotype of our COPD 
patients who had no significant reversibility of their airflow 
obstruction after acute inhalation of 400 µg of salbutamol.
On the other hand, during chronic treatment with formot-
erol, further improvements of FEV1 and peak expiratory flow 
following administration of salbutamol were scarce and not 
significant either at 12 or 24 weeks of therapy, at least eight 
hours after LABA administration (Figure 1 and Table 2).
In contrast, the forced vital capacity increment after the 
highest cumulative dose of salbutamol was greater and still 
significant at 12 weeks and 24 weeks of therapy with   formoterol. 
The aim of the study was to measure functional changes and 
not clinical improvement, and a similar trend was observed for 
inspiratory capacity in three tidally flow-limited and dynami-
cally hyperinflated COPD patients at rest (Table 2).
Some speculation can be made regarding these findings. 
It is well known that peak expiratory flow and FEV1 changes 
are sensitive to a decrease in airflow resistance, mainly in the 
large and medium caliber airways, while the forced vital 
capacity changes reflect a diminution of air trapping (ie, 
plethysmographic residual volume) because of reduction of 
airflow resistance in the small airways and their closure at 
lower lung volumes.17 It is conceivable that formoterol inhaled 
as a dry powder may reach the central airways and rapidly 
saturate the β2 receptors located in these airways. Therefore, 
after a few weeks of treatment with formoterol, the additional 
bronchodilating effect of salbutamol, as reflected by the peak 
expiratory flow and FEV1 changes, may be mild even at high 
doses. Conversely, the dry powder formulation of formoterol 
might have more difficulty in reaching the peripheral airways 
and occupy all β2 receptors,18 leaving salbutamol given by 
metered dose inhaler as a possible means of further dilating 
and/or reopening these airways.
Such a possibility could be enhanced by the fact that even 
if β2 adrenoreceptors are widely distributed in the bronchial 
tree, and their number increases in airway smooth muscle 
with increasing airway generation, showing higher density 
in smaller than in larger airways.19,20
Thus, the opportunity of further stimulating β2 receptors 
in the peripheral airway smooth muscle cells may allow high 
doses of salbutamol inhaled by metered dose inhaler to sub-
stantially increase forced vital capacity (and decrease air 
trapping) by reducing expiratory airflow resistance at low 
lung volumes, even after many weeks of treatment with 
formoterol (Figure 1). Such reasoning may also explain the 
inspiratory capacity changes observed in three of our COPD 
patients, in whom baseline inspiratory capacity was markedly 
reduced because of dynamic pulmonary hyperinflation due 
to resting tidal expiratory flow limitation.5
The choice of focusing the effect on lung function fol-
lowing increasing doses of salbutamol on top of regular 
treatment with formoterol eight hours after its morning dose 
was based on the widely recognized fact that the bronchodi-
lating effect of a pure β2 agonist such as formoterol (when 
given alone) tends to decline after 8 hours (especially during 
chronic treatment). Therefore, this could be the best period 
to show a favorable effect of salbutamol. For the same reason, 
the need for COPD patients to use salbutamol as a rescue 
drug is expected to be more frequent in real life eight hours 
after a dose of formoterol.
The number of patients who completed the protocol was 
small. One third of patients dropped out for different reasons 
related to the length of the study. However, ten patients pro-
vided power of 80%, at the 5% significance level, to detect 
the same smallest clinically relevant difference of FEV1 with 
the same standard deviation of difference in FEV1 after bron-
chodilators. Nevertheless, we recognize that these results need 
to be confirmed in larger cohorts of COPD patients. However, 
to the best of our knowledge, this is the first study that inves-
tigated the effect of SABA in terms of dose-  response curve 
in stable COPD patients regularly treated with LABA for a 
long period, eventually using SABA to control sporadic acute 
symptoms or during mild worsening of their symptoms and 
not in presence of acute exacerbations.International Journal of COPD
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This was an observational study given that we could not 
include a group receiving placebo because of restrictions 
imposed by the local ethics committee arising from the dura-
tion of the study, but we believe that the reproducibility of 
FEV1 and forced vital capacity which this study assesses has 
been reported frequently enough to make this unnecessary.21
To our knowledge, no clinical and functional data have 
presently been reported about the effects of acute SABA 
administration on top of regular LABA treatment in COPD 
patients. In light of our results, we believe that a study with 
indacaterol, for instance, should be carefully performed.
In conclusion, the results of the present study suggest that 
during chronic therapy with conventional doses of formoterol 
(inhaled as a dry powder) in moderate-to-severe COPD, the 
addon use of salbutamol (by metered dose inhaler) does not 
improve peak expiratory flow and FEV1 markedly, but is still 
effective in reducing air trapping, as shown by the increase 
in forced vital capacity and possibly dynamic pulmonary 
hyperinflation in the presence of tidal expiratory flow limita-
tion at rest. However, these effects that are expected to 
diminish acute symptoms in COPD patients during long-term 
treatment with LABA, can be obtained with doses of salbu-
tamol (by metered dose inhaler) higher than 400 µg.
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